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Alterations in the expression of growth factors and their receptors are associated
with the growth and development of human tumors. One such growth factor is IGF-I
(insulin-like growth factor I ), a 70-amino-acid polypeptide expressed in many tissues,
including brain. IGF-I is also expressed at high levels in some nervous system-derived
tumors, especially in glioblastoma. When using IGF-I as a diagnostic marker, 17 dif-
ferent tumors are considered as expressing the IGF-I gene.
Malignant glioma, the most common human brain cancer, is usually fatal. Average
survival is less than one year. Our strategy of gene therapy for the treatment of
gliomas and other solid tumors is based on: 1) diagnostic using IGF-I gene expression
as a differential marker, and 2) application of “triple-helix anti-IGF-I ” therapy. In the
latter approach, tumor cells are transfected with a vector, which encodes an
oligoribonucleotide — an RNA strand containing oligopurine sequence which might be
capable of forming a triple helix with an oligopurine and/or oligopyrimidine sequence
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of the promotor of IGF-I gene (RNA-IGF-I DNA triple helix).
Human tumor cells transfected in vitro become down-regulated in the production of
IGF-I and present immunogenic (MHC-I and B7 expression) and apoptotic character-
istics. Similar results were obtained when IGF-I antisense strategy was applied. In
both strategies the transfected cells reimplanted in vivo lose tumorigenicity and elicit
tumor specific immunity which leads to elimination of established tumors.
IGF-I AND DIAGNOSTIC
There is a convergence between ontogenesis
and cancerogenesis and the same specific an-
tigens (oncoproteins) like -fetoprotein
(AFP), growth hormone (GH), and growth fac-
tors, such as IGF, FGF or EGF are present in
embryo / fetal tissues and in neoplastic devel-
oping tissues. It was demonstrated that AFP,
an oncoprotein present in different cancer tis-
sues, especially in liver cancer (Abelev, 1971)
is also present in normal developing tissues,
and particularly in the central nervous system
(CNS) (Trojan & Uriel, 1979). Similarly it was
demonstrated that IGF-I, insulin-like growth
factor I, is present both in normal developing
CNS and in neoplastic glial cells (Kiess et al.,
1989; Ayer-le-Lievre et al., 1991; Trojan et al.,
1992; Sandberg et al., 1998). The presence of
IGF-I was confirmed in different neoplastic
derivatives, including hepatic tissues, and
also using the model of murine teratocarci-
noma (Trojan et al., 1994).
IGF-I is a 70-amino-acid polypeptide involv-
ed in cell and tissue differentiation
(Daughaday et al., 1972; Froesch et al., 1985;
Han et al., 1987; Baserga, 1994; Trojan et al.,
1994). IGF-I plays an important role in growth
as a mediator of growth hormone (Froesch et
al., 1985; Johnson et al., 1991; Le Roith et al.,
2001). The action of IGF-I on cellular metabo-
lism depends on binding proteins, IGFBP,
which prolong the half life of this factor and
modify its interaction with a receptor (Jones
& Clemmons, 1995; Collet & Candy, 1998;
Rosen, 1999; Hva et al., 1999). Binding to a
specific IGF-I receptor and subsequent activa-
tion of a protein tyrosine kinase signal trans-
duction cascade, is similar to that of insulin
(Werner & Le Roith, 2000; Adams et al.,
2000). IGF-I, mediated by IGF-I receptor, has
been reported to block the apoptosis pathway
in a variety of cell lines (Rodriguez-Tarduchy
et al.,1992; D’Mello et al., 1993; Muta &
Krantz, 1993; Baserga, 1994). Conversely,
blocking IGF-I synthesis induces apoptotic
and immunogenic phenomena (Upegui-Gon-
zalez et al., 1998). However in general, the mo-
lecular mechanism of control of IGF-I expres-
sion is poorly defined. Although the IGF-I
gene consists of six exons (Daughaday &
Rotwein, 1989; Sussenbach et al., 1992), the
mature human IGF-I peptide is encoded only
by exons 3 and 4, and a similar situation was
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Figure 1. A schema of triple-helix approach with a
23 bp purine homooligonucleotide inserted into
episomal vector (plasmid).
The vector transfected to targed tumor cells encodes
RNA forming triplex with DNA of the IGF-I gene — for
details see Fig. 2.
found also in the widely studied rat model
(Adamo et al., 1994). Deregulated expression
of growth factors and/or their receptors, and
especially of IGF-I, is associated with growth
as well as with different diseases, including tu-
mors (Heldin & Westermark, 1989;
Antoniades et al., 1992; Trojan et al., 1993;
Baserga, 1994; Rubin & Baserga, 1995).
In the past few years, both laboratory inves-
tigations and population studies have pro-
vided strong circumstantial evidence that IGF
physiology influences cancer risk (Yu &
Robin, 2000; Pollak, 2000). Evidence further
suggests that certain lifestyles, such as one in-
volving a high-energy diet, may increase IGF-I
levels, a finding that is supported by animal
experiments indicating that IGFs may abolish
the inhibitory effect of energy restriction on
cancer growth (Yu & Robin, 2000).
According to Baserga (1995), IGF-I is one of
the most important growth factors related to
normal and neoplastic differentiation. IGF-I is
expressed in 17 different tumors (for refer-
ences see Trojan et al., 1993). Since the last
symposium “IGFs and Cancer”, held in Halle
in Germany (15–17.09.2000), IGF-I is consid-
ered as a diagnostic marker and a biological
modulator in different types of tumors, espe-
cially in brain tumors (Zumkeller & Westphal,
2001; Zumkeller, 2002).
The IGF system consists of IGF-I and IGF-II,
the type I and type II IGF receptors, and spe-
cific IGF binding proteins (IGFBP-1 to -6).
These factors regulate both normal and malig-
nant brain growth. Enhanced expression of
IGF-I and IGF-II mRNA transcripts has been
demonstrated in gliomas, meningiomas, and
other tumors. Abnormal imprinting of IGF-II
occurs in gliomas, medulloblastomas, and
meningiomas (Zumkeller & Westphal, 2001).
Both types of IGF receptor are expressed in
gliomas and, in particular, the type I IGF re-
ceptor appears to be upregulated in malignant
brain tissue. Meningiomas and, to a lesser de-
gree, malignant gliomas were found to synthe-
sise IGFBP-1, supporting the notion that
IGFBPs contribute towards the growth of
CNS tumors in humans; glioblastoma cell
lines were found to express mRNA for
IGFBP-1 (42% of cell lines), IGFBP-2 (65%),
IGFBP-3 (97%), IGFBP-4 (3%), IGFBP-5 (74%)
and IGFBP-6 (94%) as determined by polymer-
ase chain reaction (Zumkeller, 2002). The re-
lationship between IGF-I and IGFBP is start-
ing to be introduced in clinical diagnostics as
one of the indications of precancerous devel-
opment.
Among the numerous examples of cancer
growth and metastasis monitored by the IGF-I
marker (serum level) one should mention
colorectal cancers (Mishra et al., 1998;
Manousos et al., 1999; Giovanucci et al, 2000;
Wu et al., 2002; Bustin et al., 2002), of breast
(Vadgama et al., 1999; Campbell et al., 2001;
Helle et al., 2001; Eppler et al., 2002; Bajetta et
al., 2002), prostate cancer ( Wolk et al., 2000;
Mita et al., 2000) and of lung (Lee et al., 1999;
Yu et al., 1999; Olchovsky et al., 2002). The
role of IGFs in cancer is supported by
epidemiologic studies which have found that
high levels of circulating IGF-I and low levels
of IGFBP-3 are associated with increased risk
of several common cancers, including those of
the prostate, breast, colorectum, liver and
lung (Giovanucci, 1999; Yu & Robin, 2000).
IGF-I is an important mitogen required by
some cell types to progress from the G1 to the
S phase of the cell cycle. IGFBPs can have op-
posing actions, in part by binding IGF-I, but
also by direct inhibitory effects on target cells.
Because the tissue determinants of IGF
bioactivity appear to be regulated in parallel
with circulating IGF-I level, it is reasonable to
hypothesize that the substantial intra-
individual variability in circulating levels of
IGF-I and IGFBP-3 may be important in deter-
mining risk of some cancers. In general, two-
to four-fold elevated risk has been observed
for prostate cancer in men in the top quartile
of IGF-I relative to those in the bottom quar-
tile, and low levels of IGFBP-3 were associated
with an approximate doubling of risk. For
colorectal neoplasia, four-fold elevated risk
was observed in men and women with low
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IGFBP-3, whereas high IGF-I was associated
with a doubling of risk (Giovanucci, 1999).
IGF-I AND ANTI-GENE THERAPIES
As far as the role of oncoproteins in
tumorigenesis is concerned, different ap-
proaches of anti-tumor treatment have been
considered. The most classical was treatment
using antibodies, i.e. treatment of liver cancer
with injection of antibodies directed toward
oncoproteins like AFP. Unfortunately, this
type of technique was not specific enough for
the treated tissues (AFP like other
oncoproteins is present in different types of
differentiating cells). Following the hypothe-
sis that neoplastic differentiation is related to
the presence of oncoproteins, the arrest of
oncoprotein synthesis at the gene level
seemed to be the best way to stop tumor devel-
opment. “Anti-gene” strategies offer new pos-
sibilities for cancer therapy: antisense tech-
nique ( arresting protein synthesis at the tran-
scription level) (Rubinstein et al., 1984;
Weintraub et al., 1985; Green et al., 1986) or
triple helix technique ( stopping the synthesis
at translation level) (Dervan, 1992; Hélène,
1994).
In the past twenty years, it has been shown
that natural antisense RNA which is tran-
scribed from one strand of DNA could hybrid-
ize to the sense RNA. This natural physiologi-
cal regulation represents the basics of the
antisense approach to inhibit artificially the
expression of particular genes involved in hu-
man diseases. Using this antisense strategy,
the translation of messenger RNA (sense
RNA) can be blocked by binding a complemen-
tary strand to this mRNA. The achievement of
this artificial regulation could be done using
either short oligonucleotides delivered to cells
via appropriate carriers or by using plasmid
constructs transcribing intracellular anti-
sense RNA (Trojan et al., 1992).
IGF-I antisense gene therapy (Trojan et al.,
1993) was introduced in clinical trials to treat
hepatoma (Shanghaï, China) and glio-
blastoma (Cleveland, U.S.A., and Bydgoszcz,
Poland) (Anthony et al., 1998). Glioblastoma
is the most frequent and usually fatal tumor.
Recently some interesting results concerning
glioblastoma treatement were published by
American-Asian cooperation (Wongkajorn-
slip et al., 2001). A subject inflicted with
glioblastoma who underwent partial tumor re-
section and radiotherapy, after subcutaneous
injections of IGF-I antisense transfected
glioma cells for 8 weeks, developed peritumor
necrosis. The latter lesion was infiltrated by
lymphocytes containing both CD8 and CD4
cells. The functional activity of these lympho-
cytes was demonstrated by the active produc-
tion of interferon gamma and tumor necrosis
factor alpha.
In the triple helix (TH) technology the
oligonucleotides that block gene expression
are triple-helix forming oligonucleotides
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Figure 2. Potential struc-
ture of antiparallel
RNA–DNA–DNA triple
helix complex.
The first and second
strands are genomic
DNA (IGF-I); the third
strand is the homopurine
RNA. *****Hoogsteen hy-
drogen bonds;
IIIIIIII
Wat-
son-Crick bonds.
(TFOs). They block RNA polymerase transit
by forming a triple-helical structure on DNA
(Dervan, 1992; Hélène, 1994).
The TH strategy was applied to the ras onco-
genes which are the most frequently activated
oncogenes in human cancer. In vitro tran-
scription of human Ha-ras was inhibited by
TFOs targeted to sequences recognized by the
Sp1 transcription factor (Mayfield et al.,
1994). Using transient transfection assays, it
was demonstrated that a purine-rich TFO
could also inhibit the transcription of murine
c-Ki-ras gene in NIH 3T3 cells (Alluni-Fabroni
et al, 1996).
Growth factors are known to play a role in
tumorigenesis and thereby represent conve-
nient targets for anti-gene therapies. The syn-
thesis of human tumor necrosis factor (TNF),
which acts as an autocrine growth factor in
various tumor cell lines including neuro-
blastoma and glioblastoma, could be blocked
by TFO treatment (Aggarwal et al., 1996).
TFOs were also shown to bind in vitro to hu-
man EGF receptor promoter (Durland et al.,
1991), and to inhibit in vitro transcription of
the HER2/neu gene (Ebbinghaus et al., 1993).
The transcription of endogenous human
HER2/neu oncogene, which is overexpressed
in breast cancer and other human malignan-
cies, was inhibited by TFO treatment of a
breast carcinoma MCF-7 cell line (Porumb et
al., 1996).
More examples of the inhibitory activity of
TFO on target genes involved in tumori-
genesis are now available (Maher, 1996; Chan
& Glazer, 1997; Giovannangeli & Hélène,
1997; Vasquez & Wilson, 1998). Most of the
TFOs are targeted to polypurine and/or poly-
pyrimidine sequences located in control re-
gions of the gene of interest and are cell deliv-
ered via transfection with various chemical
carriers. An alternative way to introduce the
TFOs in the cells is to use a plasmid vector
that can drive the synthesis of the TFO RNA
inside the cells. This TFO generated in situ is
therefore protected from degradation by nu-
cleases and could reach its DNA target with-
out being trapped in lysosomal vesicles. Obvi-
ously, it could be transfected into cells via ei-
ther standard cell transfection procedures or
via ways used in virus-based gene therapy. An
application of this triplex-based approach was
used for the inhibition of the IGF-I protein in
tumorigenesis of glioblastoma and hepato-
carcinoma (Shevelev et al., 1997;
Upegui-Gonzalez et al., 2001; Ly et al., 2001).
The IGF-I triple helix (IGF-I TH) strategy
shows that an RNA strand containing a
23-nucleotide (nt) oligopurine sequence may
be capable of forming a triple helix in cultured
human primary glioma or rat C6 cells with an
oligopurine and/or oligopyrimidine sequence
of the IGF-I gene. Although we can not ex-
clude other mechanisms, triple helix forma-
tion remains the most plausible explanation
for the inhibition in expression of the IGF-I
gene (Shevelev et al., 1997). The 23-nucleotide
target regions are also present in other
growth factors, such as IGF-II or FGF. These
target regions are composed only of A and G
bases, but their sequence is different in differ-
ent growth factors. For example, the IGF-I
gene expressed in glioblastoma has a
23-nucleotide target region different from the
IGF-II gene in neuroblastoma (Trojan et al.,
non published data).
Another way of using TFO delivered inside
the cells via transcription of a plasmid vector
was recently described with the IGF-I receptor
gene in glioblastoma cells (Rininsland et al,
1997).
IGF-I TRIPLE-HELIX THERAPY:
APOPTOTIC AND IMMUNE
MECHANISMS
To demonstrate that IGF-I, and not another
factor, plays a really important role in neo-
plastic diseases, gene therapy based on IGF-I
TH approach was applied for experimental
gliomas (Shevelev et al., 1997; Ly et al., 2001).
This method gave as good results as the IGF-I
antisense strategy applied previously for ex-
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perimental glioma, teratocarcinoma and
hepatoma treatement (Trojan et al., 1993;
1994; 1996; Lafarge-Frayssinet et al., 1997;
Upegui-Gonzalez et al., 1998; Ellouk- Achard
et al., 1998).
In the IGF-I antisense strategy, the
transfectants lost tumorigenicity and induced
a T-cell mediated immune reaction both
against themselves and against their non
transfected tumorigenic progenitor cells in
syngeneic animals. Consequently, these cells
were shown to elicit a curative anti-tumor im-
mune response with tumor regression at dis-
tal sites.
C6 glioma cells transfected with an IGF-I TH
vector displayed morphological changes,
upregulation of MHC class I antigens and B7
antigen, followed by apoptosis similarly to the
IGF-I antisense transfectants (Trojan et al.,
1996; Ly et al., 2000). Moreover, they in-
creased expression of the protease nexin I
(Shevelev et al., 1997). Dramatic inhibition of
tumor growth occurred in nude mice follow-
ing injection of the transfected C6 cells
(Shevelev et al., 1997). Similar results of the
IGF-I TH strategy were obtained using a
syngeneic model of PCC3 derived mouse tera-
tocarcinoma (Ly et al., 2000). We have con-
cluded that the IGF-I TH strategy can parallel
the antisense approach and should be very
useful in anti-tumor gene therapy.
The role of both B-7 and MHC-I antigens in
the induction of T cell immunity against tu-
mors has been extensively investigated
(Linsley et al., 1990; Freeman et al., 1991;
Chen et al., 1992; Harding et al., 1992; Guo et
al., 1994). The explanation of B-7 appearance
in the IGF-I TH transfected cells would be as
follows: in our work, the transfected cells were
growing in a culture medium containing a
high concentration of a fetal calf serum
(15–20%), while non transfected cells were
maintained in a low concentration (5–8%).
This could lead to a higher activation of IGF-I
receptor (a tyrosine kinase); IGF-I and -II pres-
ent in a fetal calf serum, as well as
intracellular IGF-II act via the type-1 IGF-I re-
ceptor (Baserga, 1995; Lafarge-Frayssinet et
al., 1997). There is a relation between the sig-
nal transduction pathway of a tyrosine kinase
and the induction of B7 molecules (Schwartz,
1992; Satoh et al., 1995; Angelisova et al.,
1996); the enhancement in B7 co-stimulation
through a cAMP mechanism linked to the ty-
rosine kinase activity of the CD28 receptor
has been demonstrated (Schwartz, 1992).
As to the MHC-I expression, down-re-
gulation of MHC-I due to the action of IGF-I
has been reported for experiments with rat
thyroid cells (Saji et al., 1992). This would be
in agreement with the results reported here
concerning the inverse correlation between
IGF-I and MHC-I protein expression in glioma
cells. Moreover, using tumor cells transfected
with a IGF-I TH vector, we found increased
level of TAP-1 and -2 in these cells, explaining
also the presence of MHC-I (Ly et al., 2001).
The mechanism of apoptosis is related to the
receptor of IGF-I (a tyrosine kinase), itself re-
lated to phosphorylation of IRS-1 (insulin re-
ceptor substrate) (D’Ambrosio et al., 1996).
For this reason different researchers have
tried to stop the apoptotic effect using the
antisense approach to IGF-I receptor (Sell et
al.,1993; Baserga et al., 1994; Resnicoff et al.,
1994; Valentinis et al., 1994). In glioma cells,
the absence of IGF-I, caused by IGF-I anti-
sense or triple-helix technologies, is associ-
ated with massive apoptosis (Ly et al., 2000;
2001). There is a relationship between the im-
mune process, related to the MHC-I or the
HLA system (Blanchet et al., 1992), and the
apoptotic process — both phenomena simulta-
neously increasing or decreasing in IGF-I TH
transfectants (Ly et al., 2001 ). Recently it was
demonstrated that dendritic cells which are
involved in tumor-immunogenicity mecha-
nisms by activation of lymphocytes CD8 in the
context of MHC-I, recognize apoptotic cells
(Matthew et al., 1998).
The IGF-I TH technology was also investi-
gated using the model of mouse hepatoma
(Upegui-Gonzalez et al., 2001). The IGF-I TH
transfected hepatoma cells also stopped pro-
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ducing IGF-I, and recovered MHC-I expres-
sion accompanied by apoptosis but were
down-regulated in the production of IL-10 and
TNF-. Injection of the transfected cells into
mice bearing hepatoma at terminal-phase sig-
nificantly prolonged their survival. The re-
sults suggest that injection of hepatoma cells
transfected using the TH approach could con-
stitute a vaccine against hepatoma. To our
knowledge, we are the first to obtain in vivo re-
sults with RNA–DNA triple helix produced af-
ter plasmid vector transfection in vitro. The
TH strategy for clinical gene therapy of tu-
mors is currently being introduced in Univer-
sity Hospitals of Krakow (digestive tube can-
cer and liver cancer) and of Bydgoszcz
(glioblastoma), Poland. Our IGF-I TH treat-
ment is registered by the international Wiley
Gene Therapy Databases — No. 635 and 636
(Gene Therapy Clinical Trials, updated Sep-
tember, 2001 by the Journal of Gene Medi-
cine). The first clinical results obtained with
glioblastoma and colon cancer are very prom-
ising. The results related to IGF-I TH treat-
ment of colon cancer (five cases to date) are
undergoing evaluation and will be published
next year. For comparative purposes we have
also explored the possibility of using our TH
strategy for the therapy of other tumors ex-
pressing IGF-I such as breast, prostate and
ovary cancers. The latter cancers will be
treated at the University Hospital of
Bydgoszcz in 2003.
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